Skip to content

TransCelerate Event

Webinar: Vulcan UDP (Utilizing the Digital Protocol): Collaborating to Accelerate ICH M11 and End User Value 

Watch this webinar to learn about Vulcan’s Utilizing the Digital Protocol (UDP), an umbrella project that brings together multiple initiatives to develop a digital representation of a study protocol.

Slides can be viewed here. Watch the webinar here.

During the webinar, our panelists:

  • Outlined the goals of the UDP project, addressing the who, what, when, where, and why aspects.
  • Delivered a summary of the first UDP Connectathon in May, highlighting the feedback, key learnings, and planned follow-up actions.
  • Described the intent and potential impact of M11 from the ICH M11 perspective.
  • Announced the upcoming UDP Connectathon in September, detailing its goals and objectives, providing information on where to find more details, and explaining how to participate.
  • Facilitated a Q&A at the end of the webinar.

Panelists:

  • Hugh Glover, Technical Director, Vulcan
  • Mary Lynn Mercado, Global Head Protocol Delivery & US Site Head, Regulatory Writing & Submissions, Novartis
  • Chris Decker, President and CEO, CDISC
  • Ron Fitzmartin, Senior Advisor, Office of Regulatory Operations, CBER FDA  
  • Noemie Manent, Clinical Trial Transformation (CTT) Change Manager, EMA

Ideal Attendees for Webinar Recording:

  • Anyone interested in Clinical Data Interoperability
    • Solution Providers that utilize clinical protocol information, such as:
      • Study builders and authoring platforms 
      • Structured content management tools 
  • Sponsors and CROs involved in processes that consume protocol information, such as:
    • Protocol and Development Authoring  
    • Clinical Trial Digital and Technology Support 
    • Regulatory Operations, submissions & document management 
    • Data Manager; Innovation Manager, Infrastructure Manager, Programmers in Clinical Development
  • Health Authorities: clinical trial regulators, regulatory submission review (i.e., FDA and EMA)